Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma clinical trial (NCT05874414). Contact the study team or your healthcare provider for specific answers.

Question 2

How does GNS561 and trametinib compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma clinical trial (NCT05874414). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of this combination treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma clinical trial (NCT05874414). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma clinical trial (NCT05874414). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my condition worsens while participating in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma clinical trial (NCT05874414). Contact the study team or your healthcare provider for specific answers.

Question 6

Will my insurance cover the costs associated with this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma clinical trial (NCT05874414). Contact the study team or your healthcare provider for specific answers.

What this study is about